360 related articles for article (PubMed ID: 24285312)
41. Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier.
Dörner B; Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Mairinger S; Löscher W; Müller M; Langer O; Erker T
J Med Chem; 2009 Oct; 52(19):6073-82. PubMed ID: 19711894
[TBL] [Abstract][Full Text] [Related]
42. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
43. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
44. ABC transporters and the blood-brain barrier.
Begley DJ
Curr Pharm Des; 2004; 10(12):1295-312. PubMed ID: 15134482
[TBL] [Abstract][Full Text] [Related]
45. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
Rowbottom C; Pietrasiewicz A; Tuczewycz T; Grater R; Qiu D; Kapadnis S; Trapa P
Pharmacol Res Perspect; 2021 Apr; 9(2):e00740. PubMed ID: 33660938
[TBL] [Abstract][Full Text] [Related]
46. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
[TBL] [Abstract][Full Text] [Related]
48. Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain Barrier.
Nieto Montesinos R; Béduneau A; Lamprecht A; Pellequer Y
Mol Pharm; 2015 Nov; 12(11):3829-38. PubMed ID: 26390138
[TBL] [Abstract][Full Text] [Related]
49. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.
Elsinga PH; Hendrikse NH; Bart J; Vaalburg W; van Waarde A
Curr Pharm Des; 2004; 10(13):1493-503. PubMed ID: 15134571
[TBL] [Abstract][Full Text] [Related]
50. Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier.
Raaphorst RM; Windhorst AD; Elsinga PH; Colabufo NA; Lammertsma AA; Luurtsema G
Clin Pharmacol Ther; 2015 Apr; 97(4):362-71. PubMed ID: 25669763
[TBL] [Abstract][Full Text] [Related]
51. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier.
Sharma V; Prior JL; Belinsky MG; Kruh GD; Piwnica-Worms D
J Nucl Med; 2005 Feb; 46(2):354-64. PubMed ID: 15695797
[TBL] [Abstract][Full Text] [Related]
52. Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly.
Miller DS
Adv Cancer Res; 2015; 125():43-70. PubMed ID: 25640266
[TBL] [Abstract][Full Text] [Related]
53. Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?
Breuil L; Marie S; Goutal S; Auvity S; Truillet C; Saba W; Langer O; Caillé F; Tournier N
J Cereb Blood Flow Metab; 2022 Jan; 42(1):175-185. PubMed ID: 34496661
[TBL] [Abstract][Full Text] [Related]
54. Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
Pottier G; Marie S; Goutal S; Auvity S; Peyronneau MA; Stute S; Boisgard R; Dollé F; Buvat I; Caillé F; Tournier N
J Nucl Med; 2016 Feb; 57(2):309-14. PubMed ID: 26585058
[TBL] [Abstract][Full Text] [Related]
55. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats.
Potschka H; Baltes S; Löscher W
Epilepsy Res; 2004 Feb; 58(2-3):85-91. PubMed ID: 15120740
[TBL] [Abstract][Full Text] [Related]
57. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.
Gedeon C; Behravan J; Koren G; Piquette-Miller M
Placenta; 2006; 27(11-12):1096-102. PubMed ID: 16460798
[TBL] [Abstract][Full Text] [Related]
58. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
Kawamura K; Yamasaki T; Yui J; Hatori A; Konno F; Kumata K; Irie T; Fukumura T; Suzuki K; Kanno I; Zhang MR
Nucl Med Biol; 2009 Apr; 36(3):239-46. PubMed ID: 19324269
[TBL] [Abstract][Full Text] [Related]
59. PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
Yamasaki T; Kawamura K; Hatori A; Yui J; Yanamoto K; Yoshida Y; Ogawa M; Nengaki N; Wakisaka H; Fukumura T; Zhang MR
Nucl Med Commun; 2010 Nov; 31(11):985-93. PubMed ID: 20859232
[TBL] [Abstract][Full Text] [Related]
60. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
